AssayQuant is committed to helping you and the scientific community improve productivity and achieve challenging goals. We view our relationships with our customers as partnerships and embrace sharing our expertise and innovation with you and your organization.
Listed below are resources for our innovation and technology. Don't hesitate to contact us and let us know how we can help support your drug development and research efforts.
Our technology is well validated with over 100 publications using the Sox-based format published in leading scientific journals. Click here for a complete list of publications from the scientific community and see below for a summary of efforts by the Imperiali laboratory.
AssayQuant Technologies co-founders Dr. Barbara Imperiali and Dr. Erik Schaefer have authored over 250 peer-reviewed publications.
Use of the sulfonamido-oxine (Sox) fluorophore to report kinase activity via Chelation-Enhanced Fluorescence (ChEF) is covered by nine patents that are exclusively licensed by MIT to AssayQuant Technologies, Inc.
Click here to read Dr. Imperiali's "Perspectives on the Development of the PhosphoSens® Kinase Assay Technology".
August 2, 2022 – Vibliome Therapeutics and AssayQuant Technologies, Inc. Establish Collaborative Relationship (press release).
September 15, 2021 – AssayQuant reaches 375 validated PhosphoSens kinase, phosphatase and lipid kinase (DGK) assays in their product catalog.
May 5, 2021 – AssayQuant closes Series A Funding.
October 2020 – Patent granted for "Kinase and/or Phosphatase Sensing via Hydroxyquinoline-Sensitized Chelates," patent exclusively licensed from MIT to AssayQuant Technologies, Inc.
January 2, 2019 – AssayQuant completes 1st 254 validated PhosphoSens assays.
January 15, 2018 - AssayQuant launches partnership with Carna Biosciences to distribute exclusively PhosphoSens assay products and services in Japan.
May 12, 2016 - AssayQuant enters strategic partnership with 21st Century Biochemicals, Inc.
July 9, 2015 - AssayQuant Technologies, Inc., founded by Drs. Barbara Imperiali (CTO) & Erik Schaefer (President & CSO).
AQT has a very active new product and technology development program. Our leadership is frequently presenting at meetings and customer sites (in person or by TC) to inform groups on our capabilities. To request a presentation to learn how we can enable your drug development program, a copy of a recent presentation or to inquire about, contact us.